In 2020, at age 67, Dana was stunned to learn she had late-stage, low-grade serous ovarian cancer, as she had previously undergone a radical hysterectomy 15 years prior. Unfortunately, cancer cells had likely been left behind and had now spread into her omentum and colon.
After consulting with her physician, she underwent an eight-hour surgery and had 27 pounds of cancer removed from her body. Meanwhile, her oncologist sent a biopsy retrieved from the surgery to Caris for molecular profiling.
Once the Caris profiling results returned, she and her doctor reviewed her specific
treatment options based on the report’s findings. It was determined that the best course
of treatment was not traditional chemotherapy, as Dana’s cancer was in fact hormone-driven. Her oncologist recommended that she start and remain on letrozole, a type of hormone therapy drug.
Today, Dana remains cancer-free and has become an advocate for molecular profiling. She believes that anyone with cancer should have a molecular profile report done.
Learn more about Caris molecular profiling: www.carislifesciences.com/
#cancersurvivor
#precisionmedicine
#cancerdiagnosis
#cancerpatient